Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
Public ClinicalTrials.gov record NCT00134485. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia
Study identification
- NCT ID
- NCT00134485
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2005 (Type not available)
- Primary completion
- Not listed
- Completion
- Mar 2006 (Type not available)
- Last update posted
- Oct 30, 2007
2005 – 2006
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | San Diego | California | 92120 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20037 | — |
| Pfizer Investigational Site | Lutz | Florida | 33549 | — |
| Pfizer Investigational Site | Tampa | Florida | 33603 | — |
| Pfizer Investigational Site | Tripler AMC | Hawaii | 96859-5000 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60610 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46260 | — |
| Pfizer Investigational Site | Iowa City | Iowa | 52242 | — |
| Pfizer Investigational Site | Auburn | Maine | 04210 | — |
| Pfizer Investigational Site | Scarborough | Maine | 04074 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02111 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28204 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53719 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00134485, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2007 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00134485 live on ClinicalTrials.gov.